caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.
Status:
Active, not recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a phase II non-randomised and non-comparative study, in pretreated mCRC patients,
progressed after at least 2 lines of prior chemotherapy for metastatic disease.
Treatment plan:
- First Stage: A total of 22 patients will be enrolled in the first stage to detect at
least 3 patients free of progression at 16 weeks
- Second Stage: If at least 3 patients will be free of progression at 16 weeks, an
additional cohort of 11 patients will be enrolled in the second stage